Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01435226 · ClinicalTrials.gov registry record · Phase 2
GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
NCT01435226 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 170 participants.
The verdict
NCT01435226, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
Study Summary
This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared with GS-5885, GS-9451 with Tegobuvir or RBV in Treatment-Experienced Subjects with Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection.
Interventions
- DRUG GS-5885
- DRUG GS-9451
- DRUG tegobuvir
- DRUG placebo to match tegobuvir
- DRUG placebo to match RBV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01435226
The ClinicalTrials.gov registry entry for NCT01435226 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which GS-5885 is the first listed.
NCT01435226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01435226 about?
NCT01435226 is a clinical study titled "GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection". This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared with GS-5885, GS-9451 with Tegobuvir or RBV in Treatment-Experienced Subjects with Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection.
What is the current status of trial NCT01435226?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2011-09. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01435226?
The interventions under investigation include: GS-5885 (DRUG), GS-9451 (DRUG), tegobuvir (DRUG), placebo to match tegobuvir (DRUG), placebo to match RBV (DRUG).
Who is sponsoring clinical trial NCT01435226?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.